drugset / Trial / NCT06842992
A Phase II Study to Evaluate NH102 for Depression
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine . It is designed to preliminarily assess the efficacy and safety of NH102 in patients with major depressive disorder and to provide the basis for the design of Phase III clinical trials.
Timeline
- Start
- 2024-12-04
- Primary completion
- 2025-07-30
- Completion
- 2025-09-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Duloxetine | Small molecule | 30 mg | — |
| Subject | NH102 | Unknown | 10 mg | — |
| Subject | NH102 | Unknown | 20 mg | — |
| Subject | NH102 | Unknown | 30 mg | — |